Clinical Trial

MRD-positive AML Clinical Study

Recruiting
View on ClinicalTrials.gov →
Summary
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.
Protocol Amendment History 4 changes
notable Enrollment increased: 120 -> 537 participants 2026-08-11
minor Trial arms changed: 7 -> 9 2026-08-11
notable Primary completion pushed: 2026-05-10 -> 2028-05-10 2026-08-11
minor Completion pushed: 2028-04-30 -> 2028-10-30 2026-08-11
Trial Details
NCT Number NCT07131059
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions AML, Adult
Enrollment 537 participants
Start Date 2024-05-11
Primary Completion 2028-05-10 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-10